Pertuzumab -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of this report is to assess the added benefit of pertuzumab in combination with trastuzumab and docetaxel compared with trastuzumab / taxane (docetaxel, paclitaxel) as appropriate comparator therapy (ACT) in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer and compared with radiotherapy in patients with HER2-positive locally recurrent unresectable breast cancer.

http://ift.tt/2ssnHYq